Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and whatnot has predictably returned. To cope, we are undertaking what is surely a familiar ritual by now — brewing cups of stimulation to fire up the neurons. We need all the help we can get. Our choice today, by the way, is hazelnut creme, for those tracking this sort of thing. And now, here are a few tidbits to help you along. Hope your day is smashing and do stay in touch.

Experimental drugs from Roche (RHHBY) and Eli Lilly (LLY) failed to halt Alzheimer’s disease in their latest test in a blow to people whose genes make them particularly vulnerable to the illness, Reuters reports. The studies focused on rare autosomal dominant Alzheimer’s disease, which is caused by gene mutations that follow generations of families. A pair of separate Roche studies of its drug against a form of Alzheimer’s disease not directly caused by gene mutations would continue. It is due to produce results in 2022.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.